{"nctId":"NCT01877837","briefTitle":"Stem Cell Transplantation for Sickle Cell Anemia","startDateStruct":{"date":"2011-06"},"conditions":["Sickle Cell Disease"],"count":30,"armGroups":[{"label":"Related donor","type":"EXPERIMENTAL","interventionNames":["Drug: Alemtuzumab","Drug: Fludarabine","Drug: Melphalan","Procedure: Stem Cells"]}],"interventions":[{"name":"Alemtuzumab","otherNames":["Alemtuzumab (Campath)"]},{"name":"Fludarabine","otherNames":["Fludarabine (Fludara)"]},{"name":"Melphalan","otherNames":["Melphalan (Alkeran)"]},{"name":"Stem Cells","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient Eligibility\n\n  1\\) Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single or double) with a total TNC dose of greater than 5 x 107/kg recipient weight)\n  1. Age 2-30\n  2. Hb SS, S-thal0, S-thal+, SC\n  3. Evidence of ongoing hemolysis: Hb\\<10, retic \\>5%, LDH \\> 500, TB\\>2\n  4. Karnofsky/Lansky score \\>50\n  5. LVSF\\>26% or LVEF\\>40%\n  6. DLCO \\>40% or O2 sat \\>85% for those patients that can't perform PFTs\n  7. GFR \\>70 and serum creatinine \\< 1.5 \\* ULN for age\n  8. ALT and AST \\< 5 x ULN, direct bilirubin \\<2 x ULN\n  9. If the patient has been on chronic transfusion or has a ferritin \\>1000, liver biopsy should be done and show no evidence of bridging fibrosis or cirrhosis\n* Exclusion criteria\n\n  1. Evidence of uncontrolled bacterial, viral, or fungal infection within one month prior to initiation of the conditioning regimen\n  2. Pregnant or breastfeeding\n  3. HIV positive\n  4. Written informed consent not obtained","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Graft Failure","description":"Primary endpoint:\n\nIn each group, the Number of participants with Graft Failure at the 2 years endpoint will be estimated using the Kaplan Meier product limit estimator.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Secondary endpoints:\n\nOverall survival: The distribution of time to death from any cause will be estimated by Kaplan- Meier product limit function and plotted. The overall survival will be measured from the time of transplant to any death and patients will be followed for 2 years.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":25},"commonTop":[]}}}